Disclosed are fused pyrimidine compounds, salts, tautomers, and stereoisomers of formula (I), wherein the substituents are as described within the specification. Examples of compounds of formula (I) include: 6-phenyl-7-(4-{ [4-(3-pyridin-2-yl-1,2,4-triazol-5-yl)piperidin-1-yl]methyl} phenyl)imidazo[1,2a]-pyrimidine and Ethyl-6-phenyl-7-(4-{ [4-(5-pyridin-2-yl-1,2,4-triazol-3-yl)piperidin-1- yl]methyl} phenyl)imidazo[1,2-a]pyrimidine-2-carboxylate. Further disclosed is a pharmaceutical composition comprising at least one compound of formula (I), and a combination comprising one or more compounds of formula (I) and one or more second active agents selected from chemotherapeutic anti-cancer agents and target anti-cancer agents. Also disclosed is the of a compound of formula (I) for the production of a pharmaceutical composition for the treatment, prevention or amelioration of a disease mediated by a dysregulated function of a single protein kinase or multiple protein kinases and/or disorders responsive to the induction of apoptosis, and the treatment of benign and/or malignant neoplasia and cancer.
